Original Article

T-Cell Prolymphocytic Leukemia: An Experience from a Tertiary Cancer Centre in South India

Abstract

Background: T-cell prolymphocytic leukemia (T-PLL) is a rare lymphoid malignancy with dismal prognosis. Most patients have increased lymphocyte count (>1,00,000/dL) and widespread disease at presentation. Despite high response rate seen with alemtuzumab, the disease relapse is inevitable.
Materials and Methods: This was a retrospective observational study done at a tertiary cancer center in South India. All patients diagnosed with T-PLL from August 2010 to July 2015 were studied for the clinical characteristics, pathological findings and treatment outcomes.
Results: Seven patients were diagnosed as T-PLL over a period of 5 years. The median age at diagnosis was 51 years. In the present series, 6 patients (86%) had splenomegaly and 3 had hepatomegaly (43%). Generalized lymphadenopathy was seen in 4 (57%) patients at presentation. Skin lesions were seen in 5 (71%) patients, whereas pleural effusion was seen in only one patient (14%). All had elevated total leukocyte count, with more than 1, 00,000/dL in 4 patients. The median survival was 5 months with different chemotherapy (CT) regimens (5 patients treated with CT and 2 received best supportive care).
Conclusion:T-PLL is a rare disease with no definite treatment guidelines. At present, the best outcomes are achieved if treatment with alemtuzumab is followed by stem cell transplant, but the disease invariably relapses. Countries where affordability remains a big challenge, the best approach needs to be defined beyond the monoclonal antibodies and transplant.

Catovsky D, Galetto J, Okos A, et al. Prolymphocytic leukaemia of B and T cell type. Lancet. 1973; 2(7823):232-4.

Catovsky D, Ralfkiaer E, Muller-Hermelink HK. T-cell prolymphocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001:195-196.

National cancer institute sponsored study of classifications of Non-Hodgkin’s Lymphomas: summary and description of a working formulation for clinical usage. The NonHodgkin’s Lymphoma pathologic classification project. Cancer. 1982; 49(10): 2112–35.

Stansfeld A, Diebold J, Kapanci Y, et al. Updated kiel classification for lymphomas. Lancet. 1988; 1(8580):292-3.

Harris NL, Jaffe ES, Stein H, et al. A revised EuropeanAmerican classification of lymphoid neoplasms: a proposal from the international lymphoma study group Blood. 1994; 84(5): 1361–92.

Matutes E, Brito-Babapulle V, Yullie MR, et al. Prolymphocytic leukemia of B- and T-cell types. In: Cheson BD, ed. Chronic Lymphoid Leukemias. New York, Basel: Marcel Dekker, Inc; 2001:525-541.

Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 1991; 78(12):3269-74.

Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001; 98(6):1721–6.

Keating MJ, Cazin B, Coutré S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002; 20(1):205–13.

Robak T, Robak P. Current treatment options in prolymphocytic leukemia. Med Sci Monit. 2007; 13(4):RA69–80.

Dearden CE. T-cell prolymphocytic leukemia. Med Oncol. 2006; 23(1):17– 22.

Catovsky D, Ralfkiaer E, Muller-Hermelink HK. T-cell prolymphocytic leukemia. Pathology and genetics of tumours of haemopoietic and lymphoid tissues. In Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organisation Classifcation of Tumours. Lyon, France: IARC Press, 2008:270–271.

Dearden CE. T-cell prolymphocytic leukemia. Med Oncol. 2006; 23(1):17-22.

Matutes E. T-cell prolymphocytic leukemia. Cancer Control. 1998;5(1):19– 24

Herling M, Khoury JD, Washington LT, et al. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood. 2004; 104(2):328–35.

Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001; 98(6):1721–6.

Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol. 1997; 15(7): 2667–72.

Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002; 20(1): 205–13.

Collins RH, Pineiro LA, Agura ED, et al. Treatment of T prolymphocytic leukemia with allogeneic bone marrow transplantation. Bone Marrow Transplant. 1998; 21(6):627-8.

Curtin NJ, Schwarer AP. Nonmyeloablative peripheral blood stem cell transplant for T-cell prolymphocytic leukaemia complicated by fulminant haemolysis and acute renal failure at engraftment secondary to minor ABO incompatibility. Clin Lab Haematol. 2005; 27(3):206-8.

Hopfinger G, Busch R, Eichorst B, et al. Sequential therapy of fludarabine, mitoxantrone and cyclophosphamide (FMC) induction followed by alemtuzumab consolidation is effective and safe in patients with T-cell prolymphocytic leukemia (T-PLL): results from a multicentre phase II trial of the German CLL study group (GCLLSG) [abstract].Ann Oncol. 2011; 22(Suppl 4). Abstract 123.

Ravandi F, O'Brien S, Jones D, et al. T-Cell Prolymphocytic Leukemia: A Single-Institution Experience

Files
IssueVol 12, No 2 (2018) QRcode
SectionOriginal Article(s)
Keywords
T-cells Prolymphocytic leukemia Alemtuzumab
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Babu MC S, Anand A, Lakshmaiah KC, Babu K G, Lokanatha D, Abraham Jacob L, Madhumathi D, Lokesh KN, Rudresha A, Rajeev L, Patidar R. T-Cell Prolymphocytic Leukemia: An Experience from a Tertiary Cancer Centre in South India. Int J Hematol Oncol Stem Cell Res. 2018;12(2):132-135.